UPDATE : Friday, June 14, 2019
상단여백
‘Moon administration to expand investment into healthcare, quality of life’ by Kim Yun-mi 2019-06-14 16:49
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug by Kim Yun-mi 2019-06-12 13:29
Forxiga prevents kidney disease in diabetes patients by Kim Yun-mi 2019-06-11 15:40
HIV prevention pill to get insurance benefit in Korea by Kim Yun-mi 2019-05-30 13:25
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy by Kim Yun-mi 2019-05-29 12:35
라인
‘Enstilum treats all psoriasis from mild to severe ones’ by Kim Yun-mi 2019-05-28 14:44
‘Risk-sharing agreements back up economic feasibility review’ by Kim Yun-mi 2019-05-22 14:46
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too? by Kim Yun-mi 2019-05-21 14:19
Low-income, single women more vulnerable to osteoporosis by Kim Yun-mi 2019-05-20 15:40
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride by Kim Yun-mi 2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery by Kim Yun-mi 2019-05-15 14:14
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon by Kim Yun-mi 2019-05-13 14:23
Xeljianz is easier to use than biologic therapies -- is it safer, however? by Kim Yun-mi 2019-05-10 15:34
[Exclusive] MSD Korea playing tricks to reduce daycare cost by Kim Yun-mi 2019-05-09 11:20
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too by Kim Yun-mi 2019-05-07 14:30
라인
Leading hepatitis C drug wins FDA nod for adolescents by Kim Yun-mi 2019-05-03 15:51
New head of HUMC to put focus on research by Kim Yun-mi 2019-05-02 16:57
‘MSD Korea’s monitoring program might be privacy breach’ by Kim Yun-mi 2019-05-02 11:00
Drugmakers brace for vaccine shortage amid surging hepatitis A cases by Kim Yun-mi 2019-04-30 13:13
Breast cancer society to focus on patients’ quality of life by Kim Yun-mi 2019-04-26 14:22
여백
여백
여백
Back to Top